Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19

J Am Soc Nephrol. 2020 Jul;31(7):1384-1386. doi: 10.1681/ASN.2020050589. Epub 2020 Jun 8.
No abstract available

Keywords: COVID-19; acute renal failure; antiviral; end-stage renal disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acute Kidney Injury / diagnosis
  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / epidemiology*
  • Adenosine Monophosphate / administration & dosage
  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives*
  • Alanine / administration & dosage
  • Alanine / adverse effects
  • Alanine / analogs & derivatives*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • COVID-19
  • Cause of Death*
  • Comorbidity
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / drug therapy
  • Kidney Failure, Chronic / epidemiology*
  • Male
  • Massachusetts
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology*
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Rate

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine